Dr. Vineet Pande
Host Organization Johnson & Johnson Innovative Medicine, Belgium Computational Chemistry ALLODD Role Main Supervisor for ESR13 |
Brief Bio Vineet Pande is currently leading a team of computational chemists & data scientists at Johnson & Johnson Innovative Medicine working on several drug discovery projects in multiple therapeutic areas. He has a track-record of applying computational solutions to small molecule drug discovery programs at all stages including target-evaluation through lead-optimization, working in global matrix teams & is a co-inventor of multiple novel molecules, currently in the clinic or moving successfully towards clinical trials. He has also established and co-led various external scientific collaborations and partnerships (e.g. with the Structural Genomics Consortium), integrating diverse disciplines of drug discovery and exploring emerging external science. Before joining Janssen in 2011, he gained extensive postdoctoral research experience in computational biophysics, computer-aided molecular design, and chemical biology at Karolinska Institute, AstraZeneca R&D and EMBL, respectively. Vineet holds a Masters in biological sciences and a Ph.D. degree in computational chemistry. Selected Publications Brehmer, D.; Beke, L; Wu, T. et al. Discovery and pharmacological characterization of JNJ-64619178, a novel small molecule inhibitor of PRMT5 with potent antitumor activity Mol. Cancer Ther. 2021, 20 (12), 2317. Branch, J.R.; Bush, T.L.; Pande, V. et al. Discovery of JNJ-63576253, a next-generation androgen receptor antagonist active against wild-type and clinically relevant ligand binding domain mutations in metastatic castration-resistant prostate cancer Mol. Cancer. Ther. 2021, 20 (5), 763. Pande, V.; Sun, W.; Beke, L. et al. A chemical probe for the methyl transferase PRMT5 with a novel binding mode ACS Med. Chem. Lett. 2020, 11 (11), 2227. Embrechts, W.; Herschke, F.; Pauwels, F., et al. 2,4-Diaminoquinazolines as dual toll-like receptor (TLR) 7/8 modulators for the treatment of hepatitis B virus J. Med. Chem. 2018, 61 (14), 6236. Muller, S.; Ackloo, S.; Arrowsmith, C.H.; et al. Donated chemical probes for open science ELife. 2018, 7:e34311. Pande, V. Understanding the complexity of epigenetic target space J. Med. Chem. 2016, 59 (4), 1299. Cabaye, A.; Nguyen, K.T.; Liu, L.; et al. Structural diversity of epigenetics pocketome Proteins 2015, 83 (7), 1316. Pande, V.; Pocalyko, D.J.; Dhanak, D. Emerging epigenetic therapies- lysine methyltransferase/PRC complex inhibitors. In book: Epigenetic Cancer Therapy (Academic Press) 2015. pp.427. Pande, V., and Nilsson, L. Insights into structure, dynamics, and hydration of locked nucleic acid (LNA) strand-based duplexes from molecular dynamics simulations Nucleic Acids Res. 2008, 36 (5), 1508. |
|
|
This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956314.
|
|